Summary
Assessing mutagenicity, the capacity of a substance to cause permanent and potentially harmful changes to an organism's DNA, is a pivotal concern in drug development. This assessment is crucial because it helps to predict the carcinogenic potential of new pharmaceuticals, ensuring that they are safe for human use. The importance of evaluating mutagenicity in drug development cannot be overstated. Drugs are designed to interact with biological systems to treat or prevent diseases, but they must do so without causing harmful genetic alterations. The process of developing a new drug involves a complex, time-consuming, and costly sequence of research and testing to ensure efficacy and safety. If mutagenicity is not accurately assessed, the consequences can be severe. Addressing the complexities and limitations associated with assessing mutagenicity in drug development, an innovative approach utilizing artificial intelligence (AI) and whole genome sequencing (WGS) data presents a promising solution. MUTAPREDICT introduces an innovative AI-driven platform designed to revolutionize the field of drug development by accurately predicting the mutagenic potential of new chemical compounds. This platform is set to address the ethical, economic, and temporal challenges associated with conventional animal testing and in vitro analyses, promoting a more humane, cost-effective, and efficient approach to drug safety assessments. Leveraging advanced WGS data, our solution significantly accelerates the drug development process, ensuring both safety and efficacy. Our value proposition encompasses ethical and sustainable drug development by offering a viable alternative to animal testing, thus meeting the growing demands for ethical research practices.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101189234 |
| Start date: | 01-10-2024 |
| End date: | 31-03-2026 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Assessing mutagenicity, the capacity of a substance to cause permanent and potentially harmful changes to an organism's DNA, is a pivotal concern in drug development. This assessment is crucial because it helps to predict the carcinogenic potential of new pharmaceuticals, ensuring that they are safe for human use. The importance of evaluating mutagenicity in drug development cannot be overstated. Drugs are designed to interact with biological systems to treat or prevent diseases, but they must do so without causing harmful genetic alterations. The process of developing a new drug involves a complex, time-consuming, and costly sequence of research and testing to ensure efficacy and safety. If mutagenicity is not accurately assessed, the consequences can be severe. Addressing the complexities and limitations associated with assessing mutagenicity in drug development, an innovative approach utilizing artificial intelligence (AI) and whole genome sequencing (WGS) data presents a promising solution. MUTAPREDICT introduces an innovative AI-driven platform designed to revolutionize the field of drug development by accurately predicting the mutagenic potential of new chemical compounds. This platform is set to address the ethical, economic, and temporal challenges associated with conventional animal testing and in vitro analyses, promoting a more humane, cost-effective, and efficient approach to drug safety assessments. Leveraging advanced WGS data, our solution significantly accelerates the drug development process, ensuring both safety and efficacy. Our value proposition encompasses ethical and sustainable drug development by offering a viable alternative to animal testing, thus meeting the growing demands for ethical research practices.Status
SIGNEDCall topic
ERC-2024-POCUpdate Date
21-11-2024
Images
No images available.
Geographical location(s)
